Laboratoires Théa SAS ("Théa") announced last Friday that it will acquire seven branded ophthalmic products from Akron Operating Company LLC.
Among these brands is Zioptan, Akron’s leading glaucoma therapy, as well as its nearly 50-person sales force, which Théa intends to expand with the anticipated launch and growth of additional products within the US, according to a news release.
In a statement, Jean-Frédéric Chibret, Théa’s president, said the acquisition is a milestone purchase for the company.
“As a fifth-generation member of a family that has spent more than150 years dedicated to eye care, I’m always excited to extend Théa’s unique expertise and passion into new markets, he said, “where our goal is to improve patient quality of life by providing innovative offerings across a full range of therapeutic areas, including glaucoma, dry eye, allergy and inflammation.”
The following Akorn brands are included in Théa’s purchase:
Théa expects to submit its first New Drug Application (NDA) with the FDA by this year’s first quarter for its version of the glaucoma treatment latanoprost.
By the end of the 2022 first quarter, the company plans to launch, in partnership with Similasan Corporation, a new line of branded over-the-counter evidence-based dry eye drops and eyelid hygiene products.